Can Plasmapheresis be Useful in the Treatment of Patients with Covid-19?
Asian Hematology Research Journal,
Page 1-4
Abstract
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) has created a pandemic throughout the world, most notably causing death owing to pneumonia and cytokine storm syndrome. The treatment is highly supportive with no definitive antiviral therapy and aims to alleviate hypercytokinemia in addition to prevent further complications during viral clearance. Therapeutic plasma exchange is the separation of plasma from other blood components and have a potential to clear cytokines which causes the “storm”. Double-Filtration Plasmapheresis is effective of removal of particles huger than 55-60 nm and the method stands the rationale of possibly clearing SARS-CoV-2 (60-140 nm) from blood. In this article we would like to highlight the beneficial potential of plasmapheresis although it’ s an unproven strategy.
Keywords:
- Plasmapheresis
- pneumonia
- cytokine
How to Cite
Bolaman, A. Z., Turgutkaya, A., & Yavaşoğlu, İrfan. (2020). Can Plasmapheresis be Useful in the Treatment of Patients with Covid-19?. Asian Hematology Research Journal, 3(3), 1-4. Retrieved from https://journalahrj.com/index.php/AHRJ/article/view/30131
References
Available:https://covid19info.live/
Availble:https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/
Barnaby Edward Young MB, BChir, Sean Wei Xiang Ong, MBBS; Shirin Kalimuddin, MPH et al. Epidemiologic features and clinical course of patients ınfected with SARS-CoV-2 in Singapore. JAMA. 2020; 323(15):1488–1494.
Ali Golchin, Ehsan Seyedjafari, Abdolreza Ardeshirylajim. Mesenchymal stem cell therapy for COVID-19: Presentor Future. Stem Cell RevRep. 2020;13:1-7.
Hung IF, To KK, Lee CK, Lee KL; Chan K, Yan WWet al. Convalescent plasma treatment reduced mortality in patientswith severe pandemicinfluenza A (H1N1) 2009 virusinfection. ClinInfect Dis. 2011;52:447-56.
DOI:https:// doi: 10.1093/cid/ciq106. Epub 2011 Jan 19
Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919-922.
DOI:https://doi: 10.1093/jac/dki346
Shen Cİ Wang Z, Zhao F, Yang Y, Li J, Yuan J et al. Treatment of 5 CriticallyIll Patients With COVID-19 With Convalescent Plasma. JAMA; 2020.
DOI:https:// 10.1001/jama.2020.4783
Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020 Mar 31. pii: S0012-3692(20)30571-7.
DOİ: 10.1016/j.chest.2020.03.039
Huang C, Wang Y, Li X, et al. Clinicalfeatures of patientsinfected with 2019 novelcoronavirus in Wuhan, China. Lancet. 2020;395:497-506.
DOİ: 10.1016/S0140-6736(20)30183-5
Dennis Mc Gonagle, Kassem Sharif, Anthony O'Regan et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6): 102537.
Betts, Brian C. MD, Young, James W. MD. Less Can Be More WhenTargeting Interleukin-6-Mediated Cytokine Release
Syndrome in Coronavirus Disease 2019. Critical Care Explorations. 2020;2(6): e0138.
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30-e31.
DOI:https://doi:10.1016/S0140-6736(20)30304-4
Hollie M. Reeves, Jeffrey L Winters. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3): 342-51
Anand Padmanabhan, Laura Connelly-Smith, Nicole Aqui et al. Guidelines on the use of therapeutic apheresis in clinical practice -evidence-based approach from the writing committee of the american society for apheresis: The eighth special ıssue. J Clin Apher. 2019;34(3):171-354.
Kayo Sugimoto, Soo Ryang Kim, Ahmed El-Shamy, SusumuImoto Haruma Fujioka Ke Ih Kim, YasuhitoTanaka et al. Outcome of double-filtration plasmapheresisplus ınterferon treatment in nonrespondersto pegylated ınterferonplus ribavirin combination therapy. Dig Dis. 2013;31: 434-39
DOI:https:// D OI: 10.1159/000355241
Yu X, Ma J, Tian J, Jiang S, Xu P, Han H, Wang L. A controlledstudy of double filtration plasmapheres is in thetreatment of active rheumatoid arthritis. J Clin Rheumatol. 2007;13:193-8.
DOI:https://DOI:10.1097/RHU.0b013e318124a483
Jagdish K, Jacob S, Varughese S et al. Effect of double filtration plasmapheresis on various plasma components and patient safety: A prospective observational cohort study. Indian J Nephrol. 2017;27(5):377–383.
Toru Ishıkawa, Satoshi Abe, Yuichi Kojima et al. Prediction of a sustained viral response in chronic hepatitis C patients who under go induction therapy with double filtration plasma pheresis plus interferon-β/ribavirin. ExpTherMed. 2015; 9(5):1646–1650.
Marco Cascella, Michael Rajnik, Arturo Cuomo et al. Features, evaluation and treatment coronavirus (COVID-19). Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsisandsepticshock: A prospective, randomized, controlledtrial. IntensiveCare Med. 2002;28:1434-9.
Available:https://www.globenewswire.com/news-release/2020/04/14/2015592/0/en/US-FDA-Approves-an-Investigational-Device-Exemption-for-Spectral-Medical-PMX-to-Treat-COVID-19-Patients-Suffering-from-Septic-Shock.html
Availble:https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/
Barnaby Edward Young MB, BChir, Sean Wei Xiang Ong, MBBS; Shirin Kalimuddin, MPH et al. Epidemiologic features and clinical course of patients ınfected with SARS-CoV-2 in Singapore. JAMA. 2020; 323(15):1488–1494.
Ali Golchin, Ehsan Seyedjafari, Abdolreza Ardeshirylajim. Mesenchymal stem cell therapy for COVID-19: Presentor Future. Stem Cell RevRep. 2020;13:1-7.
Hung IF, To KK, Lee CK, Lee KL; Chan K, Yan WWet al. Convalescent plasma treatment reduced mortality in patientswith severe pandemicinfluenza A (H1N1) 2009 virusinfection. ClinInfect Dis. 2011;52:447-56.
DOI:https:// doi: 10.1093/cid/ciq106. Epub 2011 Jan 19
Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919-922.
DOI:https://doi: 10.1093/jac/dki346
Shen Cİ Wang Z, Zhao F, Yang Y, Li J, Yuan J et al. Treatment of 5 CriticallyIll Patients With COVID-19 With Convalescent Plasma. JAMA; 2020.
DOI:https:// 10.1001/jama.2020.4783
Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020 Mar 31. pii: S0012-3692(20)30571-7.
DOİ: 10.1016/j.chest.2020.03.039
Huang C, Wang Y, Li X, et al. Clinicalfeatures of patientsinfected with 2019 novelcoronavirus in Wuhan, China. Lancet. 2020;395:497-506.
DOİ: 10.1016/S0140-6736(20)30183-5
Dennis Mc Gonagle, Kassem Sharif, Anthony O'Regan et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6): 102537.
Betts, Brian C. MD, Young, James W. MD. Less Can Be More WhenTargeting Interleukin-6-Mediated Cytokine Release
Syndrome in Coronavirus Disease 2019. Critical Care Explorations. 2020;2(6): e0138.
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30-e31.
DOI:https://doi:10.1016/S0140-6736(20)30304-4
Hollie M. Reeves, Jeffrey L Winters. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3): 342-51
Anand Padmanabhan, Laura Connelly-Smith, Nicole Aqui et al. Guidelines on the use of therapeutic apheresis in clinical practice -evidence-based approach from the writing committee of the american society for apheresis: The eighth special ıssue. J Clin Apher. 2019;34(3):171-354.
Kayo Sugimoto, Soo Ryang Kim, Ahmed El-Shamy, SusumuImoto Haruma Fujioka Ke Ih Kim, YasuhitoTanaka et al. Outcome of double-filtration plasmapheresisplus ınterferon treatment in nonrespondersto pegylated ınterferonplus ribavirin combination therapy. Dig Dis. 2013;31: 434-39
DOI:https:// D OI: 10.1159/000355241
Yu X, Ma J, Tian J, Jiang S, Xu P, Han H, Wang L. A controlledstudy of double filtration plasmapheres is in thetreatment of active rheumatoid arthritis. J Clin Rheumatol. 2007;13:193-8.
DOI:https://DOI:10.1097/RHU.0b013e318124a483
Jagdish K, Jacob S, Varughese S et al. Effect of double filtration plasmapheresis on various plasma components and patient safety: A prospective observational cohort study. Indian J Nephrol. 2017;27(5):377–383.
Toru Ishıkawa, Satoshi Abe, Yuichi Kojima et al. Prediction of a sustained viral response in chronic hepatitis C patients who under go induction therapy with double filtration plasma pheresis plus interferon-β/ribavirin. ExpTherMed. 2015; 9(5):1646–1650.
Marco Cascella, Michael Rajnik, Arturo Cuomo et al. Features, evaluation and treatment coronavirus (COVID-19). Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsisandsepticshock: A prospective, randomized, controlledtrial. IntensiveCare Med. 2002;28:1434-9.
Available:https://www.globenewswire.com/news-release/2020/04/14/2015592/0/en/US-FDA-Approves-an-Investigational-Device-Exemption-for-Spectral-Medical-PMX-to-Treat-COVID-19-Patients-Suffering-from-Septic-Shock.html
-
Abstract View: 1621 times
PDF Download: 866 times
Download Statistics
Downloads
Download data is not yet available.
